Novartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indications Read more>
Lubris Biopharma announces outlicensing of its proprietary recombinant human lubricin for us in opthalmology to major pharma company. Read more>
Lubris Biopharma announces positive results of a clinical trial demonstrating significant improvement in both signs and symptoms of dry eye disease.
Results are published in the September issue of The Ocular Surface.
Lubris BioPharma CEO receives Biocom Life Science Catalyst Award Learn more >
Discovery of ‘Mother Nature’s lubricant’ leads biomedical researcher to explore new health applications Learn more >
“Transcription, translation, and function of lubricin, a boundary lubricant, at the ocular surface,” published in the Journal of the American Medical Association. JAMA Ophthalmol. 2013 Jun;131(6):766-76